...
首页> 外文期刊>Tropical Medicine and International Health: TM and IH >The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
【24h】

The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.

机译:六轮单剂量大剂量二乙基卡巴马嗪或伊维菌素对五倍体库克斯库克斯氏菌传播猴菜的影响及其对消除淋巴丝虫病的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Lymphatic filariasis (LF) is targeted for global elimination. Transmission interruption through repeated annual single-dose mass administration of anti-filarial drugs is the mainstay of the LF elimination strategy. This study examined the ability of six rounds of mass administration of diethylcarbamazine (DEC) or ivermectin (IVM) to interrupt transmission of Wuchereria bancrofti by Culex quinquefasciatus, the predominant parasite and vector species, respectively. After six rounds of mass drug administration (MDA), received by 54-75% of the eligible population (> or 15 kg body weight), the resting vector infection and infectivity rates fell by 83% and 79% in the DEC arm, 85% and 84% in the IVM arm and 31% and 45% in the placebo arm, respectively. The landing vector infection and infectivity rates fell by 83% and 94% in the DEC arm, 63% and 75% in the IVM arm and 1% each in the placebo arm, respectively. The filarial larval load per resting mosquito declined by 92% and 93% and per landing mosquito by 83%and 69% in the DEC and IVM arms, respectively. The annual infective biting rate (AIBR) fell from 735 to 93 (87%) in the DEC arm, 422 to 102 (76%) in the IVM arm and 472 to 398 (16%) in the placebo arm. The annual transmission potential (ATP) declined from 2514 to 125 (95%), 1212 to 241 (80%) and 1547 to 1402 (9%) in the DEC, IVM and placebo arms, respectively. However, mosquitoes with infection [microfilaria/larva 1/larva 2 (Mf/L1/L2)] were found in all study villages. Three of five villages in the IVM arm and two of five in the DEC arm recorded no resting mosquitoes with infective-stage (L3) larva. Although the ATP, after six rounds of MDA, fell substantially and remained at 125 and 241 in the DEC and IVM arms, respectively, the cumulative exposure to infective stage larvae (ATP) during the treatment period of 6 years was as high as 2995 in the DEC arm and 1522 in the IVM arm, because of considerable level of transmission during the initial (1-3) rounds of MDA. We conclude that (i) six rounds of MDA, even with 54-75% treatment coverage, can reduce LF transmission very appreciably; (ii) better treatment coverage and a few more rounds of MDA may achieve total interruption of transmission; (iii) high vector densities may partly nullify the reductions achieved in vector infection and infectivity rates by MDA and (iv) achievement of 'true zero' Mf prevalence in communities and 0% infection rate (mosquitoes with Mf/L1/L2) in mosquitoes may be necessary to totally interrupt Culex-transmitted LF.
机译:淋巴丝虫病(LF)的目标是全面消除。 LF消除策略的主要任务是通过每年一次单剂量大规模重复使用抗孝素药物来中断传播。这项研究检查了六轮大规模施用二乙基卡巴肼(DEC)或伊维菌素(IVM)的能力,以分别阻断库克克斯昆克法氏菌,主要寄生虫和媒介物物种对班氏假单胞菌的传播。经过六轮大规模药物管理(MDA),54%至75%的合格人群(>或15公斤体重)接受了治疗,DEC组的静息载体感染和传染率分别下降了83%和79%,85 IVM组分别为%和84%,安慰剂组分别为31%和45%。 DEC组的着陆载体感染率和感染率分别下降了83%和94%,IVM组分别下降了63%和75%,而安慰剂组分别下降了1%。 DEC和IVM臂中,每个静止的蚊子的丝虫幼虫载量分别下降了92%和93%,每个着陆蚊子的丝虫幼虫载量分别下降了83%和69%。 DEC组的年度传染性咬伤率(AIBR)从735降至93(87%),IVM组的年度传染性咬伤率从422降至102(76%),安慰剂组从472至398(16%)。 DEC,IVM和安慰剂组的年度传播潜力(ATP)分别从2514下降至125(95%),1212下降至241(80%)和1547下降至1402(9%)。但是,在所有研究村中都发现了感染了蚊子的蚊子[微丝虫/幼虫1 /幼虫2(Mf / L1 / L2)]。 IVM分支中的五个村庄中的三个村庄和DEC分支中的五个村庄中的两个没有记录到感染级(L3)幼虫的静止蚊子。尽管经过6轮MDA治疗后ATP大幅下降,DEC和IVM组中的ATP分别保持在125和241,但在6年的治疗期内,感染期幼虫(ATP)的累积暴露高达2995。 DEC臂和IVM臂中的1522,因为在MDA的初始(1-3)回合中传输水平很高。我们得出的结论是:(i)即使有54-75%的治疗覆盖率,六轮MDA也可以显着降低LF的传播; (ii)更好的治疗范围和更多轮MDA可能完全中断传播; (iii)高密度的媒介可能会部分抵消MDA导致的媒介感染和传染率的降低,以及(iv)蚊子的Mf流行率达到“真正的零”,蚊子的Mf / L1 / L2感染率达到0%可能需要完全中断Culex传输的LF。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号